Abstract
Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase that belongs to the Insulin receptor subfamily involved as full length receptor in neural development. Even if the expression of ALK protein is down-regulated in the adults, the ALK full length is expressed in different types of tumors. Moreover, chromosomal rearrangements, involving the alk gene, can occur leading to the formation of different ALK fusion proteins characterized by the kinase domain of ALK fused to several partners that determine cellular localization. Structural investigation and characterization of the ALK kinase domain in absence of its crystal structure constituted the basis of development of ALK small molecule inhibitors. Here, we described normal function of the ALK receptor and its role in tumors; formation of the constitutively activated ALK fusion proteins and we reported an update of developed small molecule inhibitors of the ALK kinase activity.
Keywords: Anaplastic Lymphoma kinase (ALK), Modeling, Molecular targeting, Oncogenic fusion protein, Small molecule inhibitors, Targeted cancer therapy, tyrosine kinase, alk gene, constitutively activated ALK fusion proteins, non-Hodgkin's lymphoma, Immunohystochemical studies, pleiotrophin(PTN) and midkine (MK), histological defects, glioblastoma, breast cancer
Current Topics in Medicinal Chemistry
Title: The ALK Gene, An Attractive Target for Inhibitor Development
Volume: 11 Issue: 11
Author(s): Carmen J. Tartari, Leonardo Scapozza and Carlo Gambacorti-Passerini
Affiliation:
Keywords: Anaplastic Lymphoma kinase (ALK), Modeling, Molecular targeting, Oncogenic fusion protein, Small molecule inhibitors, Targeted cancer therapy, tyrosine kinase, alk gene, constitutively activated ALK fusion proteins, non-Hodgkin's lymphoma, Immunohystochemical studies, pleiotrophin(PTN) and midkine (MK), histological defects, glioblastoma, breast cancer
Abstract: Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase that belongs to the Insulin receptor subfamily involved as full length receptor in neural development. Even if the expression of ALK protein is down-regulated in the adults, the ALK full length is expressed in different types of tumors. Moreover, chromosomal rearrangements, involving the alk gene, can occur leading to the formation of different ALK fusion proteins characterized by the kinase domain of ALK fused to several partners that determine cellular localization. Structural investigation and characterization of the ALK kinase domain in absence of its crystal structure constituted the basis of development of ALK small molecule inhibitors. Here, we described normal function of the ALK receptor and its role in tumors; formation of the constitutively activated ALK fusion proteins and we reported an update of developed small molecule inhibitors of the ALK kinase activity.
Export Options
About this article
Cite this article as:
J. Tartari Carmen, Scapozza Leonardo and Gambacorti-Passerini Carlo, The ALK Gene, An Attractive Target for Inhibitor Development, Current Topics in Medicinal Chemistry 2011; 11 (11) . https://dx.doi.org/10.2174/156802611795589593
DOI https://dx.doi.org/10.2174/156802611795589593 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of PET/CT and SPECT/CT in Oncology Drug Development
Current Molecular Imaging (Discontinued) Advances in Sickle Cell Disease Treatments
Current Medicinal Chemistry Gene therapy for Multiple Myeloma
Current Gene Therapy Atypical GTPases as Drug Targets
Anti-Cancer Agents in Medicinal Chemistry Ruthenium Complexes as Anticancer Agents
Current Medicinal Chemistry In vitro Biological Activity Studies of Platinum Group Metal Complexes Containing N, N'- Bis(picolinoyl)hydrazine Ligand
Current Inorganic Chemistry (Discontinued) Viral Anti-Inflammatory Reagents: The Potential for Treatment of Arthritic and Vasculitic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Surface-Functionalized Particles: From their Design and Synthesis to Materials Science and Bio-Applications
Current Organic Chemistry Effects of Drug Transporters on Pharmacological Responses and Safety
Current Drug Metabolism Turning Tumor-Promoting Copper into an Anti-Cancer Weapon via High-Throughput Chemistry
Current Medicinal Chemistry Old Drugs-Current Perspectives
Current Pharmacogenomics Multifaceted Mechanisms for Cell Survival and Drug Targeting in Chronic Myelogenous Leukemia
Current Cancer Drug Targets Metallothioneins and Cancer
Current Protein & Peptide Science Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion
Current Vascular Pharmacology Lipoxygenase Inhibitors as Cancer Chemopreventives: Discovery, Recent Developments and Future Perspectives
Current Medicinal Chemistry Biofunctional Peptides from Milk Proteins: Mineral Binding and Cytomodulatory Effects
Current Pharmaceutical Design Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review
Current Topics in Medicinal Chemistry The Intermediate Enzymes of Isoprenoid Metabolism as Anticancer Targets
Anti-Cancer Agents in Medicinal Chemistry Bcl-2 Family Proteins as Therapeutic Targets
Current Pharmaceutical Design In Vivo Treatment Efficacy of Essential Oil Isolated from Seeds of <i>Momordica charantia</i> in Streptozotocin-Induced Diabetes Mellitus
Recent Patents on Biotechnology